Is FMR’s 43% Stake Cut Reshaping the Investment Case for Day One Biopharmaceuticals (DAWN)?

Simply Wall St

Sun, February 15, 2026 at 12:14 PM GMT+9 3 min read

In this article:

DAWN

+3.18%

On December 31, 2025, FMR LLC cut its stake in Day One Biopharmaceuticals by 4,380,660 shares, reducing its position by 43.38% but still holding 5,717,008 shares, or 5.60% of the company.

This large adjustment by a major institutional shareholder highlights how concentrated ownership in a young biotech can quickly reshape investor perceptions of its prospects.

We’ll now examine how FMR LLC’s reduced ownership position may influence Day One Biopharmaceuticals’ existing investment narrative built around OJEMDA and pipeline concentration.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Day One Biopharmaceuticals Investment Narrative Recap

To be a shareholder in Day One Biopharmaceuticals today, you need to believe OJEMDA can support the business while a still‑narrow pipeline matures. The big short term catalyst remains upcoming financial and clinical updates around OJEMDA performance, and FMR LLC’s 43.38% position cut does not directly change those fundamentals, though it may heighten attention on ownership concentration and sentiment risk.

Against this backdrop, the recent preliminary 2025 OJEMDA revenue update, with full year net product revenue of about US$155.4 million and Q4 2025 revenue of US$52.8 million, is particularly relevant. It underlines how much of the current story rests on a single approved product, which can amplify both the upside from execution and the downside if growth slows, especially as investors reassess exposure after a large institutional holder trims its stake.

But investors should also be aware of the risk that heavy dependence on one U.S. focused drug could become far more important if…

Read the full narrative on Day One Biopharmaceuticals (it’s free!)

Day One Biopharmaceuticals’ narrative projects $371.5 million revenue and $40.5 million earnings by 2028. This requires 25.6% yearly revenue growth and a $135.5 million earnings increase from -$95.0 million today.

Uncover how Day One Biopharmaceuticals’ forecasts yield a $22.25 fair value, a 96% upside to its current price.

Exploring Other Perspectives

DAWN 1-Year Stock Price Chart

Some of the lowest ranked analysts were already more cautious, assuming about US$269.4 million of revenue and US$43.8 million of earnings by 2028, and when you combine that with concerns about a single U.S. drug and FMR’s reduced stake, you can see how views on Day One’s path forward might shift in very different directions from here.

Explore 4 other fair value estimates on Day One Biopharmaceuticals - why the stock might be worth just $22.25!

La historia continúa  

Build Your Own Day One Biopharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Day One Biopharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Our free Day One Biopharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Day One Biopharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include DAWN.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email [email protected]_

Condiciones y Política de privacidad

Privacy Dashboard

More Info